Stock Events

Corvus Pharmaceuticals 

€1.96
2
+€0+0% Friday 06:02

Statistics

Day High
1.96
Day Low
1.96
52W High
-
52W Low
-
Volume
0
Avg. Volume
-
Mkt Cap
118.29M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

6MayConfirmed
Q2 2022
Q3 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-0.32
-0.25
-0.18
-0.11
Expected EPS
-0.11
Actual EPS
-0.12

People Also Follow

This list is based on the watchlists of people on Stock Events who follow C17.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Bristol-Myers Squibb
BMY
Mkt Cap91.1B
Bristol Myers Squibb competes in the oncology segment, developing treatments that overlap with Corvus Pharmaceuticals' focus on cancer immunotherapy.
Merck &
MRK
Mkt Cap329.42B
Merck is a leading pharmaceutical company with a strong presence in cancer treatment, directly competing with Corvus in the immunotherapy space.
Gilead Sciences
GILD
Mkt Cap82.18B
Gilead Sciences has a significant focus on oncology and immuno-oncology, areas where Corvus Pharmaceuticals is actively developing therapies.
Astrazeneca
AZN
Mkt Cap239.29B
AstraZeneca operates in various therapeutic areas, including cancer, where its development of immunotherapies competes with Corvus' pipeline.
Pfizer
PFE
Mkt Cap158.72B
Pfizer has a broad portfolio that includes oncology, competing with Corvus Pharmaceuticals in the development of cancer treatments.
Novartis
NVS
Mkt Cap223.59B
Novartis is a global healthcare company with a strong emphasis on research and development in oncology, making it a direct competitor to Corvus.
Roche
RHHBY
Mkt Cap173.95B
Roche, through its Genentech division, is a leader in biotechnology focusing on oncology, which competes with Corvus Pharmaceuticals' focus areas.
AMGEN
AMGN
Mkt Cap166.38B
Amgen focuses on human therapeutics, including oncology and hematology, areas where Corvus is seeking to make advancements.
Regeneron Pharmaceuticals
REGN
Mkt Cap105.12B
Regeneron Pharmaceuticals is involved in the discovery and development of pharmaceutical products for the treatment of serious medical conditions, including cancer, competing with Corvus.
Incyte
INCY
Mkt Cap11.91B
Incyte Corporation specializes in oncology products, directly competing with Corvus Pharmaceuticals in the development of cancer therapies.

About

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.
Show more...
CEO
Dr. Richard A. Miller M.D.
Employees
28
Country
US
ISIN
US2210151005
WKN
000A2AFXS

Listings